Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Soticlestat (OV935) is a potent, selective and orally active cholesterol 24-hydroxylase (CYP46A1) inhibitor. It has the potential for epilepsy syndromes research.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 14,000 | |||
5 mg | 在庫あり | ¥ 34,000 | |||
10 mg | 在庫あり | ¥ 55,000 | |||
25 mg | 在庫あり | ¥ 110,000 | |||
50 mg | 在庫あり | ¥ 158,000 | |||
100 mg | 在庫あり | ¥ 228,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 37,500 |
説明 | Soticlestat (OV935) is a potent, selective and orally active cholesterol 24-hydroxylase (CYP46A1) inhibitor. It has the potential for epilepsy syndromes research. |
In vitro | Soticlestat inhibits the catalytic activity of human cholesterol 24-hydroxylase (CH24H) in a concentration-dependent manner with an IC50?of 4.5 nM |
In vivo | Soticlestat treatment lowers brain 24S-hydroxycholesterol in a dose-dependent manner and substantially reduceds premature deaths of APP/PS1-Tg mice at a dose lowering brain 24S-hydroxycholesterol by approximately 50%. Soticlestat can suppress potassium-evoked extracellular glutamate elevations in the hippocampus |
別名 | TAK-935, OV935 |
分子量 | 373.45 |
分子式 | C23H23N3O2 |
CAS No. | 1429505-03-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (267.77 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Soticlestat 1429505-03-2 Metabolism P450 Inhibitor CYP46A1 inhibit TAK935 cholesterol 24-hydroxylase NMDA antiepileptic TAK-935 OV935 OV 935 CYPs epilepsy TAK 935 OV-935 Cytochrome P450 inhibitor